Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?

Glioblastoma (GBM) is the most malignant primary brain tumor without effective therapies. Since bevacizumab was FDA approved for targeting vascular endothelial growth factor receptor 2 (VEGFR2) in adult patients with recurrent GBM, targeted therapy against receptor tyrosine kinases (RTKs) has become...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Anna, Musket, Anna, Musich, Phillip R, Schweitzer, John B, Xie, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598918/
https://www.ncbi.nlm.nih.gov/pubmed/34806012
http://dx.doi.org/10.1093/noajnl/vdab133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598918/
https://www.ncbi.nlm.nih.gov/pubmed/34806012
http://dx.doi.org/10.1093/noajnl/vdab133

Ejemplares similares